Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
https://doi.org/10.14412/1995-4484-2003-1331
Abstract
Objective. To assess homocystein (HC) level in systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) and its relation to thrombosis development and blood lipide spectrum disturbances. Material and methods. 32 pts (12 male and 20 female) with mean age 36 12 years and mean disease duration 13 11 years were included. 8 pts had SLE without APS, 13 - SLE with APS and 11 - primary APS (PAPS). All pts were divided into 2 groups depending on blood HC level. 26 pts with HC level more than 12 mcg/d! were included In group 1 and 6 pts with HC level less than 12 mcg/dl - in group 2. HC level was measured with high efficacious liquid chromatography (HELC). Lipid-protein blood spectrum was assessed in all pts. Results. Elevated HC level was revealed in 26 from 32 pts: in 16 with SLE (including 12 pts with APS) and in 10 with PAPS. HC concentration did not depend on APS presence, but frequence of hyperhomocysteinemia (HHC) significantly associated with APS and thrombotic complications. 20 from 26 (76,9%) pts with HHC had thrombosis history. Only I from 6 (16,7%) pts with normal HC level had thrombosis history (exact Fisher test p=0,02). HC level did not depend on age and sex. Changes of blood lipid-protein indices were revealed in most pts. Lipid spectrum disturbances were confined largely to cholesterol elevation due to increase of atherogenic lipoproteins cholesterol. Only 22% of pts showed decrease of antiatherogenic lipoproteins concentration. Bblood lipid-protein spectrum indices did not depend on HC level. Conclusion. HHC is present in 84,6% of pts with APS (primary and secondary). In pts with APS HHC is more frequent than in pts without APS. HHC is associated with thrombotic complications. HHC and lipid-protein spectrum disturbances are independent risk factors of thrombotic complications in pts with SLE and APS.
References
1. <div><p>Алекберова З.С., Попкова Т. В., Насонов Е.Л. с соавт. Липид-белковые системы транспорта холестерина у больных системной красной волчанкой в зависимости от антифосфолипндного синдрома. Тер.архив, 1999, 5, 34-38.</p><p>Баркаган З.С., Момот А.П. Основы диагностики нарушения гемостаза. М., Ныодиамед-АО, 1999, 215.</p><p>Насонова В.А. Системная красная волчанка. М., Медицина, 1972.</p><p>Насонов ЕЛ., Карпов Ю.А., Алекберова З.С. Антифо- сфолипидный синдром: кардиологические аспек- ты.Тер.архив, 1993,11, 5-13.</p><p>Abu-Shakra М., Urowitz М.В., Gladinan D.D. et al. Mortality studies in SLE. Results from a single center. I. Causes of death. J Rheumatol., 1995, 22,1259-1264.</p><p>Alpert M.A. Homocyst(e)ine, atherosclerosis and thrombosis. South Med. J. 1999, 92 (9). 858-865.</p><p>Asherson R.A., Rhamaihta M.A., Ordi-Ros J. et al. The "primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore), 1989, 68, 366374.</p><p>Bruce IN, Burns RJ. High prelevance of myocardial perfusion abnormalities in women with SLE. Arthr. Rheum, 1997, 40 (suppl.9), 219.</p><p>Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb. Haemost., 1999, 81, 65-76.</p><p>DAngello A., Mazzola G., Grippa L. Hyperhomocysteine- mia and venous thromboembolic disease. Haematologica,, 1997, 82, 211-219.</p><p>Exner Т., Sahman N. Trudinger B. Separation of anticar- diolipin antibodies from lupus anticoagulant on phospho- lipidcoated polysterine column. Biochem. Biophys. Res.Commun., 1988, 155, 1001-1007.</p><p>Falconi C.R., Cattaneo M. Prevalence of moderate hyper- homocysteinemia in patients with early- onset venouse and arterial occlusive disease. Ann. Intern. Med., 1995, 123, 747.</p><p>Fijnheer R. Roest М., Haas FJ. et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study J. Rheumatol., 1998, 25(9), 1737-1742.</p><p>Harker L.A., Ross R., Slichter S.J., Scott C.R. Homocysteine-induced arteriosclerosis. The role of endothelial cell injure and platelet response in its genesis. J. Clin.Invest., 1976, 58, 731-741.</p><p>Hughes G.R.V., Harris E.N., Charavi А.Е. The anlicardi- olipin syndrome. J.Reumatol., 1986, 13, 486-489.</p><p>Jensen R. The new markers of cardiovascular risk. Clin. Haemostasis Rev., 2000, 14, 1-4.</p><p>Petri М., RoubenotT R., Dallal G.E. et al. Plasma homocysteine as a risk factor for atherothroinbotic events in systemic lupus erythematosus. Lancet, 1996. 26, 348(9035), 1120-1124.</p><p>Saez G., Thornalley P.J., Hill H.A. et al. The production of free redicals during the autoxidation of cysteine and their eflecl on isolated rat hepatocytes. Biochim. Biophys., 1982. 719, 24-31,</p><p>Seriolo B., Fasciolo D., Sulli A. Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin. Exp.Rheumatol., 2001, 19(5), 561-564.</p><p>SeLhub J., Jacques P.F., Wilson P.W. et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA., 1993. 270, 2693-2698.</p><p>Starkebaum G., Harlan M. Endothelial cell injure due lo copper-catalysed hydrogen peroxide generation from homocysteine. J.Clin.Invest., 1986, 77, 1370-1376.</p><p>Svenungsson E., Jensen-Urstad K., Heimburger M. et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. J.Circulation, 2001, 16,104(16), 1887-1893,</p><p>Tan E.M., Cohen A.S., Fries J.F. et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthr. Rheum., 1982. 136, 347-354.</p><p>Tsai J-С., Perrella M.A., Yoshizumi M. et al. Promolion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc.Natl. Acad. Sci. (USA), 1994, 91, 6369-6373.</p><p>Upchurch G.R., Welch G.N. Homocysteine attenuates endothelial glutatione peroxidase and thereby potentiates peroxide-mediated cell injure. Circulation, 1995, 92, 1228.</p><p>Vianna J.K., Khamasha M.A., Ordi-Ros J., et al. Comparision of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am. J. Med., 1994, 96, 3-9.</p><p>Zmuda J.M., Bausserman L.L., Maceroni D. The effect of supraphysiologic doses of testosteroni on fasting total homocysteine levels in normal men. Atherosclerosis, 1997. 130. 199-202.</p><p>Welch G.N, Upchurch G., Loscalzo J, Hyperhomo- cyst(e)inemia and atherothrombosis. Ann. N. Y. Acad. Sci,1997, 15, 811.48-58.</p></div><br />
Review
For citations:
Shirokova I.E., Reshelnyak T.M. Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Rheumatology Science and Practice. 2003;41(4):39-43. (In Russ.) https://doi.org/10.14412/1995-4484-2003-1331
Views:
1485
Email this article 